en تخصصي Special نامه به سردبیر Letter to Editor <span style="font-size:12.0pt"><span style="line-height:200%"><span new="" roman="" style="font-family:" times="">Semaglutide, a once-weekly GLP-1 receptor agonist, has emerged as a promising therapeutic option for individuals struggling with obesity and type 2 diabetes mellitus (T2DM). Its ability to induce weight loss, reduce appetite, and improve glycemic control has led to its increasing utilization in clinical practice. Semaglutide works by mimicking the action of endogenous GLP-1, leading to enhanced insulin secretion, decreased glucagon secretion, and delayed gastric emptying</span></span></span> Semaglutide, Maxillofacial, Surgery 108 109 http://wjps.ir/browse.php?a_code=A-10-466-78&slc_lang=en&sid=1 Ricardo Grillo 100319475328460017563 100319475328460017563 Yes Oral and Maxillofacial Surgery Training Program, Foundation of Dentistry - Fundecto, University of São Paulo, São Paulo, Brazil Sahand Samieirad 100319475328460017564 100319475328460017564 No Department of Oral and Maxillofacial Surgery, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran. Bruno Alvarez Quinta Reis 100319475328460017565 100319475328460017565 No Oral and Maxillofacial Surgery Training Program, Foundation of Dentistry - Fundecto, University of São Paulo, São Paulo, Brazil Bernardo Correia Lima 100319475328460017566 100319475328460017566 No Oral Diagnosis, Dental Radiology and Imaging Postgraduate Program, School of Dentistry, University of São Paulo, São Paulo, Brazil Fernando Melhem- Elias 100319475328460017567 100319475328460017567 No Department of Oral and Maxillofacial Surgery, University of São Paulo School of Dentistry, São Paulo-SP, Brazil.